This study, to be published in Journal for Immunotherapy of Cancer, looks at the immune-related adverse event, acute interstitial nephritis (inflammation of the kidney tissues), as a biomarker for response to immune checkpoint inhibitors.
Using a database, the researchers identified 177 patients with metastatic renal cell carcinoma (RCC) who received at least one dose of immune checkpoint inhibitor. They identified a total of four patients with acute interstitial nephritis, which ranged from 1.5 to 12 months in onset after the start of treatment. All four patients stopped treatment with at least a partial recovery of renal function. All four patients had a deep response to treatment with immune checkpoint inhibitors.
In conclusion, acute interstitial nephritis is a rare event, but it may indicate a higher likelihood of response to immune checkpoint inhibitors.